{"id":169358,"date":"2026-09-18T22:40:11","date_gmt":"2026-09-18T22:40:11","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/169358\/"},"modified":"2026-09-18T22:40:11","modified_gmt":"2026-09-18T22:40:11","slug":"novo-furthers-ai-push-with-anthropic-partnership","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/169358\/","title":{"rendered":"Novo furthers AI push with Anthropic partnership"},"content":{"rendered":"<p>The basics:<\/p>\n<p><a href=\"https:\/\/njbiz.com\/tag\/novo\/\" class=\"st_tag internal_tag \" rel=\"tag nofollow noopener\" title=\"Posts tagged with Novo\" target=\"_blank\">Novo<\/a> will use <a href=\"https:\/\/njbiz.com\/tag\/anthropic\/\" class=\"st_tag internal_tag \" rel=\"tag nofollow noopener\" title=\"Posts tagged with Anthropic\" target=\"_blank\">Anthropic<\/a> Claude <a href=\"https:\/\/njbiz.com\/tag\/ai\/\" class=\"st_tag internal_tag \" rel=\"tag nofollow noopener\" title=\"Posts tagged with AI\" target=\"_blank\">AI<\/a> models in <a href=\"https:\/\/njbiz.com\/tag\/rd\/\" class=\"st_tag internal_tag \" rel=\"tag nofollow noopener\" title=\"Posts tagged with R&amp;D\" target=\"_blank\">R&amp;D<\/a> workflows<br \/>\nPartnership will support <a href=\"https:\/\/njbiz.com\/tag\/drug-discovery\/\" class=\"st_tag internal_tag \" rel=\"tag nofollow noopener\" title=\"Posts tagged with drug discovery\" target=\"_blank\">drug discovery<\/a>, biological research<br \/>\nAnthropic technology will also support AI-driven software development<br \/>\nDeal follows Novo\u2019s AI partnerships with OpenAI, AWS<\/p>\n<p>Novo is adding Anthropic to its growing list of technology partners as the pharma giant looks to use artificial intelligence to speed up <a href=\"https:\/\/njbiz.com\/tag\/drug-research\/\" class=\"st_tag internal_tag \" rel=\"tag nofollow noopener\" title=\"Posts tagged with drug research\" target=\"_blank\">drug research<\/a> and development.\n<\/p>\n<p>The company <a href=\"https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html?_sp=db2a0e8a-3562-40ff-8d14-5856281716bb.1789662583905&amp;id=916768\" target=\"_blank\" rel=\"noopener nofollow\">announced the partnership Sept. 16.<\/a> Novo will initially tap Anthropic\u2019s Claude AI models for specific R&amp;D workflows. Financial terms were not disclosed.\n<\/p>\n<p>The collaborators said that work will include using the technology to help scientists address drug discovery challenges, analyze biological questions and identify areas where AI could have the greatest impact.<\/p>\n<p>The relationship also includes using Anthropic\u2019s technology to support AI-driven software development at Novo, the partners said.\n<\/p>\n<p>According to Novo, the collaboration will include data-governance measures and human oversight.\n<\/p>\n<p>All in on AI<\/p>\n<p>The relationship with Anthropic is the latest in a series of AI initiatives at Novo.<\/p>\n<p>In April, <a href=\"https:\/\/njbiz.com\/novo-nordisk-openai-ai-drug-development\/\" target=\"_blank\" rel=\"noopener nofollow\">the company unveiled a partnership with OpenAI. <\/a>As part of that arrangement, Novo said it will use OpenAI\u2019s capabilities to analyze complex datasets, identify promising drug candidates and reduce the time from research to patient.\n<\/p>\n<p><a href=\"https:\/\/njbiz.com\/novo-nordisk-aws-ai-drug-discovery\/\" target=\"_blank\" rel=\"noopener nofollow\">Last month, Novo announced a partnership with Amazon Web Services.<\/a> The company will use AWS on AI projects involving drug discovery and the analysis of genomic, imaging and clinical data.\n<\/p>\n<p>As a leading global healthcare company, Novo employs about 66,700 people in 80 countries. Its <a href=\"https:\/\/njbiz.com\/novo-nordisk-wegovy-pill-tops-3m-prescriptions\/\" target=\"_blank\" rel=\"noopener nofollow\">key medicines include<\/a> GLP-1 drugs Ozempic for type 2 diabetes and Wegovy for weight management. Headquartered in Denmark, Novo has its U.S. base in Plainsboro.\n<\/p>\n<p><a href=\"https:\/\/www.anthropic.com\/news\/claude-for-life-sciences\" target=\"_blank\" rel=\"noopener nofollow\">It joins other pharmaceutical companies, such as Sanofi, Genmab and AbbVie,<\/a> in using Anthropic\u2019s Claude platform for research, development and other operations.\n<\/p>\n<p>Other technology companies are partnering with drugmakers across the industry, including NVIDIA, Microsoft and Google. Those collaborations focus on applying AI to areas like <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10385763\/#sec10-pharmaceutics-15-01916\" target=\"_blank\" rel=\"noopener nofollow\">identifying drug candidates, analyzing biological data and streamlining the development process.<\/a>\n<\/p>\n<p>Supercharging R&amp;D<\/p>\n<p>Novo CEO and President Mike Doustdar said the Anthropic partnership \u201cis another testament to our ambition to become the world\u2019s most AI-driven healthcare company.\u201d\n<\/p>\n<p>\u201cJoining forces with Anthropic will supercharge our R&amp;D organization and help us on our mission to bring new, transformative health solutions to people living with chronic diseases,\u201d he said.\n<\/p>\n<p>Joining forces with Anthropic will supercharge our R&amp;D organization and help us on our mission to bring new, transformative health solutions to people living with chronic diseases.<br \/>\u2013 Mike Doustdar, CEO and president, Novo<\/p>\n<p>\u201cAI can help us increase productivity in R&amp;D and compress the path from research to marketed product. But beyond this, AI tools can also offer completely new scientific opportunities and aid reasoning and understanding of human biology and drug mechanics,\u201d the CEO added.\n<\/p>\n<p>Anthropic co-founder and CEO Dario Amodei remarked, \u201cAI\u2019s increasing capability brings with it the potential to compress a century\u2019s worth of biological and medical breakthroughs into a decade.\u201d\n<\/p>\n<p>He said, \u201cBy giving leading researchers access to safe, capable, and trusted frontier models, we can shorten research timelines, improve outcomes, and discover medicines and treatments that significantly improve human life. That is exactly what our collaboration with Novo is built to achieve.\u201d\n<\/p>\n<p>The partnership comes days <a href=\"https:\/\/njbiz.com\/novo-nordisk-rebrand-novo\/\" target=\"_blank\" rel=\"noopener nofollow\">after Novo revealed a rebrand<\/a>. Along with an updated version of its Apis bull logo and new slogan, \u201cLasting Health Starts Now,\u201d the company shortened its name from Novo Nordisk to Novo.<\/p>\n","protected":false},"excerpt":{"rendered":"The basics: Novo will use Anthropic Claude AI models in R&amp;D workflows Partnership will support drug discovery, biological&hellip;\n","protected":false},"author":2,"featured_media":169359,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[248,34067,16749,77964,3845,272,27560,50893],"class_list":["post-169358","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-ai","tag-anthropic","tag-drug-discovery","tag-drug-research","tag-novo","tag-novo-nordisk","tag-pharmaceutical-industry","tag-rd"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117294453662399769","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/169358","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=169358"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/169358\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/169359"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=169358"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=169358"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=169358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}